ML-IAP Inhibitors

The inhibitors targeting ML-IAP function predominantly as Smac mimetics or IAP antagonists. Smac (Second Mitochondria-derived Activator of Caspases)/DIABLO is a mitochondrial protein that promotes apoptosis by neutralizing IAPs. Smac mimetics like AT-406, LCL161, Birinapant, and GDC-0152 mimic Smac's function, leading to the degradation of IAPs, including ML-IAP. These compounds bind to IAPs and promote their auto-ubiquitination and proteasomal degradation, thus facilitating the apoptosis process that ML-IAP normally inhibits. In addition to Smac mimetics, other compounds like Embelin and MV1 target XIAP (X-linked inhibitor of apoptosis protein) and cIAP1 (cellular inhibitor of apoptosis protein 1), which are closely related to ML-IAP. By inhibiting these proteins, these compounds indirectly influence ML-IAP's role in apoptosis. Tolinapant, for instance, is a dual cIAP1/2 and XIAP inhibitor, reducing the overall anti-apoptotic threshold of the cell, indirectly affecting ML-IAP.

The chemical class of ML-IAP inhibitors includes diverse molecules that target various points in the IAPs pathway. This diversity indicates the complex regulation of apoptosis and the multiple ways by which IAPs, including ML-IAP, can be modulated. These inhibitors are crucial for understanding the molecular mechanisms of apoptosis regulation and offer potential avenues for cancer therapy, as the overexpression of IAPs is a common feature in many cancers. By targeting IAPs, these compounds aim to restore the apoptotic balance in cells.